Immediate Impact
1 from Science/Nature 65 standout
Citing Papers
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Enhancing immunotherapy with tumour-responsive nanomaterials
2025 Standout
Works of Michael Li being referenced
Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
2020
Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Michael Li | 160 | 60 | 40 | 73 | 68 | 29 | 359 | |
| Jesse Civan | 208 | 74 | 47 | 55 | 75 | 35 | 407 | |
| Elena Tenti | 167 | 45 | 58 | 103 | 53 | 34 | 369 | |
| Francesca Comito | 127 | 96 | 36 | 76 | 58 | 25 | 320 | |
| Jin Gu | 164 | 78 | 91 | 87 | 72 | 33 | 393 | |
| Jian‐Guo Hong | 152 | 81 | 48 | 51 | 90 | 30 | 300 | |
| Wenyu Zhang | 111 | 51 | 30 | 118 | 53 | 39 | 374 | |
| Frank Seebach | 154 | 61 | 77 | 105 | 42 | 35 | 388 | |
| Giulia Rovesti | 153 | 85 | 55 | 118 | 66 | 27 | 372 | |
| Nikolai Jaschke | 94 | 130 | 53 | 93 | 49 | 24 | 357 | |
| Jiansheng Li | 140 | 53 | 74 | 135 | 30 | 29 | 378 |
All Works
Login with ORCID to disown or claim papers
Loading papers...